some reading on both dndn & onty

some article on the net about our 'big brother' and 'sister' DNDN & ONTY, good read to kill some time when it appears a little quiet on the PRR thread.

http://seekingalpha.com/article/309205-trade-ideas-from-last-week-s-big-biotech-news-movers

Trade Ideas From Last Week's Big Biotech News Movers

Dendreon Corp. (DNDN): We reviewed DNDN shortly after it reported disastrous Q3 results on November 2nd, and continue to believe that DNDN, while being disappointing, is not a short at these levels due to the risk of an upside surprise. Furthermore, for those with a strong appetite for risk, the stock’s technical action over the past week along with the fundamental backdrop discussed above seem to indicate that the stock may have hit at least an intermediate-term bottom for now.
.....

Oncothyreon Inc. (ONTY): ONTY develops synthetic vaccines and targeted small molecules for cancer immunotherapy and management. Its primary product candidate, Stimuvax is in phase 3 clinical trials for the treatment of non-small cell lung cancer (NSCLC). Its shares were higher by 15.3% during the week, after it presented data early Monday morning from the phase 1 portion of its phase 1/2 trial of PX-866 in combination with chemotherapy agent docetaxel.

--------------------------------------------------
While many are still talking about DNDN when discussing PRR, I'm more interested in ONTY's development due to its strong tie with Prima in terms of technology family and patent history, especially in the coming 2012 when their PhaseIII result is due out. And some in the known (including MR) had mentioned before that ONTY would worth some/more attention from PRR followers. It's good that this article had both covered.


Go PRR!